Humanin Peptide Dosage Protocol: A Physician's Guide to Dosing, Timing, and Administration

At a Glance

Humanin is among the most clinically interesting of the mitochondria-derived peptides (MDPs). It was discovered in 2001 while searching for genes that protect neurons from Alzheimer’s-related damage, and it turned out to be encoded in mitochondrial DNA [1]. It has since been shown to regulate apoptosis, modulate insulin sensitivity, suppress neuroinflammation, and signal through the gp130/JAK/STAT3 pathway shared with IL-6 — making it fundamentally different in character from structural peptides like BPC-157 or growth hormone secretagogues.

Humanin is discussed in two main contexts: as a neuroprotective adjunct for people with post-infectious cognitive impairment or early neurodegeneration, and as a metabolic sensitizer in longevity-focused protocols where mitochondrial efficiency is the target. When I help patients make an informed decision about it, both contexts require careful dose selection, because no human data define an effective dose, which leaves no room for the casual “more is more” thinking that infiltrates peptide communities online.

What humanin is and what it does

Humanin is a short peptide coded by a small open reading frame inside the mitochondrial 16S ribosomal RNA gene. In the original 2001 study, it rescued cultured neurons from cell death triggered by familial Alzheimer’s disease genes and amyloid-beta [1]. Later work showed it is produced in the body and circulates in blood [4].

Two findings explain the longevity interest:

• Levels change with age and hormones. Circulating humanin declines with age in mice and humans. Growth hormone or IGF-I treatment lowered humanin levels in both mice and people, and long-lived growth-hormone-deficient mice had higher levels [2].
• More humanin, better healthspan markers in animals. Overexpressing humanin extended lifespan in the worm C. elegans. In middle-aged mice, twice-weekly treatment with a potent humanin analogue (HNG) improved metabolic healthspan measures and lowered inflammatory markers. In humans, the children of centenarians had higher circulating humanin than age-matched controls [3].

In mice, acute humanin treatment also reduced heart-muscle damage after an experimental heart attack [5]. These findings are either in animals or observational in humans; no published trial has yet given humanin to people as a treatment.

What the evidence shows

Preclinical

Human

Why Dosage Precision Matters More with Humanin Than Most Peptides

No one has measured what a given injected dose of humanin does to blood levels in people, and no human study has defined an effective or a toxic dose. The doses in community use (milligrams per injection) are far above the amounts that circulate naturally, so they are pharmacological rather than replacement doses. Whether that matters for benefit or harm is unknown. Cycling is a community convention; there are no data on tolerance to humanin.

Circulating humanin levels decline with age, and growth hormone or IGF-I treatment lowers them further [2]. That provides a rational basis for interest in supplementation in aging patients. But it also underlines that the goal of exogenous humanin is restoration of physiological signalling, not pharmacological super-saturation.

Protocol table: doses at a glance

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

No human dosing trial of humanin or of its potent analogue HNG (S14G-humanin) has been published. Every human dose below is a community or reference-site convention, and the only administered doses with published outcomes come from animals.

Units matter. Every community and reference source I could find gives milligrams (0.5-5 mg per injection). Microgram figures (2-10 mcg per injection) also circulate online, but I found no source behind them; they are 100 to 1,000 times lower. No dose in either unit has been tested in a person.

Humanin or HNG. HNG is reported to be roughly 1,000-fold more potent than native humanin in preclinical models, and most community users say they are injecting HNG. The same aggregator notes that vendor labelling of which form is in the vial is inconsistent, so users often do not know which peptide, at which potency, they are taking.

Why the mouse dose is not a human dose. The best-documented animal regimen is HNG at 4 mg/kg twice weekly by intraperitoneal injection for 14 months in middle-aged mice, which improved metabolic healthspan measures and lowered inflammatory markers [3]. Some community pages scale this allometrically to about 20 mg per human dose. That is arithmetic, not a tested dose, and it is far above what users actually inject.

Cycling and stopping. Community patterns run 4 to 12 weeks with 2 to 4 week breaks. There are no data on what happens to blood humanin, glucose or anything else after stopping.

Technique, reconstitution and storage are in the peptide injection guide.

Standard Dosing Tiers

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

These tiers follow the protocol table above. They come from community and reference-site conventions, not from a human dose-finding trial.

Starting range: 0.5–1 mg daily, or 1–3 mg twice weekly

The low daily pattern (0.5–1 mg once daily for 4–8 weeks) and the lower twice-weekly range (1–3 mg) are the usual entry points in community reports (Anecdotal). Users describe effects as subtle, emerging after about two to four weeks if at all.

Common range: 1–5 mg per injection, 2–3 times weekly

This is the most common community pattern for longevity and metabolic goals, run for 4–8 weeks on and 2–4 weeks off, with some sources using 8–12 weeks (Practice protocol: Peptide Protocol Wiki, Peptide DB). The same 1–5 mg range is used with neuroprotection in mind (Anecdotal).

Baseline labs should be drawn prior to initiation — at minimum fasting glucose, fasting insulin, HbA1c, IGF-1, and a lipid panel — because humanin modulates insulin signaling and lipid metabolism in ways that warrant objective monitoring rather than symptom tracking alone.

Higher range: 5 mg twice weekly (5–10 mg per week)

Forum users describe a fixed weekly total of 5–10 mg, usually as 5 mg twice weekly or 5 mg once weekly, in blocks of 2–4 weeks on and 2–4 weeks off; one user ran 8 weeks (Anecdotal).

Vials labelled as HNG: 0.5–2 mg twice weekly

Because HNG is reported to be far more potent than native humanin in preclinical models, reference sites list a lower range for it (Anecdotal). Labelling is inconsistent, so the vial may not contain what it says.

The mouse regimen (HNG 4 mg/kg twice weekly) works out at roughly 20 mg per dose when scaled allometrically to a human, well above any of these tiers; nobody has tested that scaling in people.

Administration Routes and Practical Guidance

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Subcutaneous Injection

Subcutaneous (SC) injection into the abdomen, lateral thigh, or upper arm remains the gold-standard route for humanin delivery. The peptide has a short plasma half-life estimated at 15–30 minutes in rodent models, which means peak receptor engagement occurs rapidly post-injection and the brief exposure window actually reduces downstream desensitization.

Reconstitution: Humanin typically arrives lyophilized. Reconstitute with bacteriostatic water (not sterile water). As an example of the arithmetic, 10 mg dissolved in 2 mL gives 5 mg/mL, so 1 mg is 0.2 mL and 2.5 mg is 0.5 mL on an insulin syringe. Most 1/2” 29–31 gauge insulin syringes are appropriate.

Storage: Lyophilized vials are stable at room temperature for 3 months and should be refrigerated once reconstituted. Reconstituted peptide is stable refrigerated for 28–30 days; avoid repeated freeze-thaw cycles.

Injection timing: Morning injections in a fasted state are preferred. Humanin’s metabolic signalling intersects with the fasted-state cascade — AMPK activation, PGC-1α induction, mitochondrial biogenesis — and fasted administration may amplify these effects. Avoid co-injection with other peptides at the same site; separate sites by at least 2 cm.

Intranasal Administration

Intranasal delivery is an emerging route with a mechanistic rationale for neurological indications: the olfactory route provides direct access to the CNS via the nasal-brain pathway, bypassing the blood-brain barrier. Nasal delivery of a humanin derivative (colivelin) has been explored in mouse models of Alzheimer’s disease with promising results [7].

No human intranasal dose of humanin has been published; the only nasal data are for colivelin in mice [7]. Nasal humanin figures that circulate online (for example 50–100 mcg a day) have no source I could find, and they are far below the injected doses in community use.

This route requires a compounding pharmacy experienced with nasal peptide formulations and carries additional cost and supply-chain considerations.

Cycling Protocol and Washout

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Indefinite daily use of humanin is not a practice I endorse, and the rationale is not merely precautionary conservatism. Humanin’s cytoprotective signalling runs in part through STAT3 and PI3K/AKT, and cycling is meant to avoid adaptation to constant stimulation, but no study has measured tolerance to humanin. Cycling is a community convention.

Common cycle (Practice protocol):

• On phase: 4–8 weeks; some sources 8–12 weeks
• Off phase: 2–4 weeks

Tapering: Unlike some peptides, humanin does not require a formal taper at cycle end. Abrupt cessation carries no withdrawal risk; simply stopping is appropriate.

Repeat labs at washout end: Before beginning a subsequent cycle, repeat the metabolic panel. Tracking fasting insulin and HOMA-IR over sequential cycles provides objective data to guide the decision to continue or modify.

Stacking Considerations

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Humanin shares mechanistic territory with MOTS-c — the other major mitochondria-derived peptide — through overlapping effects on AMPK, insulin signalling, and mitochondrial biogenesis. The two peptides are not redundant, however. MOTS-c has a more pronounced effect on skeletal muscle glucose uptake and mitochondrial copy number in metabolically active tissues, while humanin’s neuroprotective and anti-apoptotic actions are more central nervous system-prominent.

Humanin + MOTS-c: A widely used combination in longevity-focused practice. Dose each separately; there is no pharmacokinetic interaction but rotating injection sites is important. Some clinicians alternate days between the two rather than co-administering on the same day.

Humanin + NAD+ precursors (NMN/NR): Rational combination — NAD+ augmentation supports the mitochondrial electron transport chain function that humanin signalling helps optimize. No interaction of concern; these can be used concurrently.

Humanin + GHK-Cu: Used where neuroprotection and anti-inflammatory effects are dual targets. GHK-Cu operates primarily in the extracellular/tissue remodelling space while humanin is intracellular and receptor-mediated; the combination is additive rather than synergistic in mechanism.

Humanin + BPC-157: BPC-157’s vagus nerve-mediated systemic anti-inflammatory effects may complement humanin’s cytoprotective mechanisms in post-infectious or post-inflammatory neurological contexts. This combination is common in post-COVID cognitive impairment protocols.

Avoid concurrent use with: mTOR activators at supraphysiological doses (there is a theoretical inverse relationship between humanin-supported autophagy signalling and sustained mTOR activation), and with STAT3 inhibitors used in oncological contexts.

No study has tested any of these combinations in humans; each additional peptide adds its own unknowns.

Who Should Not Use Humanin

The following populations warrant caution or contraindication:

• Active malignancy: Humanin’s anti-apoptotic mechanisms are cytoprotective across cell types. While this is the basis of its neuroprotective value, it creates theoretical concern in oncological settings where apoptosis of malignant cells is desired. Humanin should not be used in active cancer outside of explicitly integrated oncological protocols.
• Pregnancy and breastfeeding: No safety data exist; avoid.
• Severe autoimmune disease with active flare: Humanin modulates JAK/STAT3 signalling, which has pleiotropic immune effects; use with caution in patients on JAK inhibitors or with recent immune-mediated disease activity.
• Patients with known IGFBP-3 dysregulation: Humanin binds IGFBP-3; in settings of elevated IGFBP-3 (certain hepatic conditions, exogenous IGF-1 therapy), pharmacokinetics may be unpredictable.

Known and theoretical risks

• No human safety data. We don’t know what repeated injections do to the immune system, metabolism or any organ over months or years.
• The cancer question. Humanin’s defining property is that it helps cells resist programmed cell death. That is useful for stressed neurons. It is a theoretical concern for anyone with a known or undiagnosed cancer, where cell death is exactly what treatment aims for. This risk is unproven, and it has not been tested either.
• Hormone interactions. Humanin levels are tied to the growth hormone and IGF-I axis [2]. How exogenous humanin interacts with that axis in people is unknown.
• Research-grade product quality. Peptides sold “for research use only” are not manufactured or tested to pharmaceutical standards. In test purchases of semaglutide from illegal online sellers, purity was 7.7 to 14.4 percent against a 99 percent label claim, and endotoxin was found in every sample [6].
• Injection-related harm. Self-injecting non-sterile products can cause local abscesses, skin infections and, rarely, bloodstream infections.

Monitoring and Outcome Benchmarks

Objective monitoring is what separates clinical peptide therapy from wellness experimentation. For humanin specifically:

Baseline and 8-week labs:

• Fasting glucose and insulin (HOMA-IR calculation)
• HbA1c
• IGF-1 and IGFBP-3
• Lipid panel with ApoB
• CBC and comprehensive metabolic panel
• If cognitive indication: baseline neurocognitive testing (MoCA or equivalent)

Regulatory status

• United States (FDA). Humanin is not an approved drug and does not appear on the FDA 503A bulks list or in category 1 (“under evaluation”) on the list updated 14 May 2026 [8].
• EU and Germany. Not authorised as a medicinal product by the EMA or the BfArM. A vial marked “research use only” is still unapproved, and its contents have not been tested for human use.
• Sport (WADA 2026). Not named on the Prohibited List, but any pharmacological substance without current approval for human therapeutic use falls under S0 and is prohibited at all times [9].

When to talk to a physician

If your interest in humanin comes from cognitive symptoms, a family history of dementia, post-viral fatigue or metabolic problems, those deserve a proper work-up: memory testing, metabolic labs, a sleep and mood assessment, and treatment of what is found. Exercise, blood-pressure control and metabolic health have far better evidence for brain health and healthy aging than any mitochondrial peptide.

If you are considering humanin, ask who manufactured the product and how its purity was tested, and go through the decision with a physician who knows your history.

Related Articles

• Humanin Peptide: Overview and Mechanisms
• MOTS-c Dosage and Protocol Guide
• Peptide Stacking Guide
• NAD+ IV Therapy: What to Expect
• Mitochondrial Dysfunction: Protocols and Treatment Approaches